Rahway: Merck, known as MSD outside of the United States and Canada, and Moderna, Inc., announced the initiation of INTerpath ...

Moderna and MSD have initiated a Phase III clinical study to evaluate mRNA-4157 (V940), an investigational individualised ...

V940, also known as mRNA-4157, is an investigational individualized neoantigen therapy (INT) that leverages a patient's unique tumor DNA sequence to stimulate a tailored antitumor immune response.

Like many bacterial proteins, Emm55, was highly immunogenic (i.e., triggers immune response), but Emm55 had a rare quality for bacterial proteins; it includes a transmembrane sequence allowing it ...

This led to the development of a fusion protein made up of a targeting antibody that binds epidermal growth factor receptor (EGFR) and an immunomodulatory moiety that is a ligand-binding sequence ...

Now it’s a bit of a marathon: we’re trying to sequence therapies in a way to provide patients ... Immunotherapy drugs like nivolumab (Opdivo) or pembrolizumab (Keytruda) stop this from happening and ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...